Marken collaborates with eLabeling organization

27-Sep-2016 - Last updated on 28-Sep-2016 at 15:49 GMT

(Image: iStock/cybrain)

Per the collaboration, Marken’s worldwide depot network will provide the infrastructure needed for Faubel to deliver its smart label technology across the clinical trials supply chain.

“Marken is constantly screening the market for new technologies and innovations and evaluating how best to implement new solutions into our service portfolio to add value to our clients,” Sascha Sonnenberg, VP Global CTD Sales and Operations, told Outsourcing-Pharma.com.

According to Sonnenberg, the Faubel Med-Label is a solution which was developed over the last seven years in close cooperation with “a major Big Pharma company,” and has been designed “to solve specific challenges and process improvement for the management of re-test dates and other variable data visible on a clinical trial label.”

“The full benefit of the Med-Label can be realized by implementing the update technologies into a global depot network enabling clients to use the technology to update re-test dates on a global basis via a central IT system,” added Sonnenberg.

Smart labels vs. eLabels

Sonneneberg explained the advantages of the smart labels are multiple, and depend on how smart label is defined. In general, two different categories are currently assessed in the clinical trial supply chain.

Smart labels use mobile devices to improve patient safety and patient compliance.

“Smart labels are offering additional options to integrate functionality such as schedules, video/animations on how to dispense medication, additional information provided, call with investigator, reminders, recalls, etc.,” explained Sonnenberg.

However, under current regulations this solution can only be used in addition to traditional label approaches.

Electronic labels, or eLabels attached directly to the medication, are designed to be compliant with current regulatory requirements, “but allowing to update certain information such as re-test date and/or protocol number,” explained Sonnenberg.

“This would result in using drug in an optimized way for pooling models,” he added. “Updating the re-test date by using such a solution, quality oversight is guaranteed and costs for updating re-test dates can be significantly reduced.”